4.5 Article

The longitudinal structure of negative symptoms in treatment resistant schizophrenia

期刊

COMPREHENSIVE PSYCHIATRY
卷 128, 期 -, 页码 -

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.comppsych.2023.152440

关键词

Schizophrenia; Negative symptoms; Motivation; Apathy; Network analysis; Longitudinal analysis

向作者/读者索取更多资源

This study found that the MAP and EE negative symptom dimensions in patients with treatment-resistant schizophrenia are independent and stable over time, with common causes of secondary negative symptoms clustering in the MAP dimension.
Background and hypothesis: The negative symptoms of schizophrenia are strong prognostic factors but remain poorly understood and treated. Five negative symptom domains are frequently clustered into the motivation and pleasure (MAP) and emotional expression (EE) 'dimensions', but whether this structure remains stable and be -haves as a single entity or not remains unclear.Study design: We examined a cohort of 153 patients taking clozapine for treatment-resistant schizophrenia in a regional mental health clinic. Patients were assessed longitudinally over a mean period of 45 months using validated scales for positive, negative and mood symptoms. Network analyses were performed to identify symptom 'communities' and their stability over time. The influence of common causes of secondary negative symptoms as well as centrality measures were also examined.Study results: Across patients at baseline, two distinct communities matching the clinical domains of MAP and EE were found. These communities remained highly stable and independent over time. The communities remained stabled when considering psychosis, depression, and sedation severity, and these causes of secondary negative symptoms were clustered into the MAP community. Centrality measures also remained stable over time, with similar centrality measures across symptoms.Conclusions: Our results suggest that MAP and EE are independent dimensions that remain highly stable over time in chronic schizophrenia patients treated with clozapine. Common causes of secondary negative symptoms mapped onto the MAP dimension. Our results emphasise the need for clinical trials to address either MAP or EE, and that treating causes of secondary negative symptoms may improve MAP.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据